Investigator's Brochure (IB) Table
Drugs
Drug Name | Drug Company | IB Date | Risk List Available? |
---|---|---|---|
Sutezolid | Global Alliance for TB Drug Development (TB Alliance) | August 2022 | |
TBI-223 | Global Alliance for TB Drug Development (TB Alliance) | August 2022 | |
Bedaquiline (TMC207) | Janssen Research & Development | October 2022 | |
Tecovirimat (TPOXX) - New - New | SIGA Technologies, Inc. | January 2024 | |
Pretomanid (PA-824) | Global Alliance for TB Drug Development (TB Alliance) | November 2023 | |
Remdesivir (Veklury) | Gilead Sciences | June 2021 | |
Letermovir | Merck | December 2022 | |
Cenicriviroc Mesylate CVC (TBR-652) | Allergan | April 2022 | |
Tenofovir Alafenamide/Elvitegravir | CONRAD | July 2019 | |
Cemiplimab (REGN2810) | Regeneron Pharmaceuticals, Inc. | September 2021 | |
Sofosbuvir/Velapatasvir (Epclusa) | Gilead | July 2016 | |
Vorinostat (Zolinza) | Merck | August 2013 | |
ABT-267, ABT 333, ABT-450 and Ritonavir | AbbVie | June 2017 | |
Dapivirine (Vaginal Ring) - New - New | International Partnership For Microbicides | November 2022 | |
Delamanid (OPC-67683) | Otsuka | May 2023 | |
Dolutegravir (GSK1349572) | ViiV Healthcare | October 2023 | |
Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) | Merck | July 2021 | |
Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada) | Gilead Sciences | December 2016 | YES |
GSK1265744 (Cabotegravir) - New - New | ViiV Healthcare | January 2024 | |
Rilpivirine (TMC278, Edurant) | Janssen Research & Development | July 2023 |
Vaccines
Vaccine Name Sort ascending | Vaccine Company | IB Date | Risk List Available? |
---|---|---|---|
VRC-HIVVCP0l 08-00-VP (FP8vl -rTTHC) | VRC/NIAID/NIH | February 2022 | |
VRC-HIVRGP096-00-VP (HIV-1 Trimer 4571 Vaccine) | VRC/NIAID/NIH | August 2023 | |
VRC-HIVRGP0106-00-VP (HIV-1 Trimer 6931 Vaccine) | VRC/NIAID/NIH | February 2022 | |
VRC-HIVMAB075-00-AB (VRC07-523LS) | VRC/NIAID/NIH | April 2023 | |
VRC-HIVMAB060-00-AB (VRC01) | VRC/NIAID | August 2019 | |
VRC-HIVMAB0115-00-AB (VRC01.23LS) | VRC/NIAID | August 2022 | |
Vesatolimod (GS-9620) - New - New | Gilead | April 2023 | |
V3G CH848 Pr-NP1, Adjuvanted and V3G CH848 mRNA-Tr2 | VRC/NIAID/NIH | May 2023 | |
Selgantolimod (GS-9688) | Gilead | January 2023 | |
RV460 (ALF43) | DAIDS/NIAID/NIH | November 2021 | |
RSV DeltaNS2-Delta1313-I1314L | LID/NIAID/NIH | February 2019 | |
RSV 6120/DeltaNS2/1030s | LID/NIAID/NIH | March 2019 | |
RSV 276 | LID/NIAID/NIH | February 2019 | |
Recombinant oligomeric gp145 C.6980 Clade C HIV Env protein | NIH/NIAID | August 2017 | |
PGT121.414.LS (VRC-HIVMAB0107-00-AB) | VCMP/NIAID/NIH | June 2023 | |
PGT121 | Beth Israel Deaconess Medical Center | September 2020 | |
PGDM1400LS (VRC-HIVMAB0112-00AB) | DAIDS/NIAID/NIH | December 2022 | |
PGDM1400 | Beth Israel Deaconess Medical Center | March 2021 | |
p24CE1/2 multivalent pDNA Vaccine expressing HIV M Group p24 Gag and p55 gag pDNA with IL-12 pDNA | NCI/NIAID/NIH | November 2017 | |
N332-GT5 gp140, Adjuvanted with SMNP | DAIDS/NIAID/NIH | June 2023 |